John G. Compton - 19 Feb 2026 Form 4 Insider Report for 20/20 Biolabs, Inc.

Role
Director
Signature
/s/ John G. Compton
Issuer symbol
N/A
Transactions as of
19 Feb 2026
Net transactions value
$0
Form type
4
Filing time
23 Feb 2026, 18:13:20 UTC
Previous filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Compton John G. Director C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG /s/ John G. Compton 23 Feb 2026 0002107487

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction Common Stock Conversion of derivative security $0 +7,669 +115% $0.000000 14,335 19 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction Series A-2 Preferred Stock Conversion of derivative security -7,669 -100% 0 19 Feb 2026 Common Stock 7,669 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.